By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Tris Pharma, Inc. 

South Brunswick  New Jersey    U.S.A.
Phone: n/a Fax:




Company News
Tris Pharma, Inc. Appoints New Chief Commercial Officer For Brand Business 3/10/2017 6:58:38 AM
Tris Pharma, Inc.’s Results From A Laboratory Classroom Study Of DYANAVEL XR In Children With ADHD Featured At APSARD 2/9/2017 11:01:47 AM
Tris Pharma, Inc. Release: FDA Accepts CCP-08 NDA For Full Review 12/21/2016 10:13:38 AM
Tris Pharma, Inc. Announces The Launch Of DYANAVEL XR (Amphetamine) Extended-Release Oral Suspension, CII For The Treatment Of Children With ADHD 4/19/2016 6:28:45 AM
Tris Pharma, Inc. Announces Appointment Of Chief Commercial Officer Of Its New Brand Business 4/7/2016 8:19:27 AM
Tris Pharma, Inc. Announces First Ever FDA-Approved Extended-Release Chewable Tablet 12/16/2015 6:45:35 AM
Tris Pharma, Inc. Receives FDA Approval Of Dyanavel XR (amphetamine) CII As Once-Daily Liquid For Treatment Of ADHD In Children 10/20/2015 7:46:45 AM
Tris Pharma, Inc. Launches Generic Tussionex As Par's Rights Expire 10/1/2015 6:39:30 AM
Tris Pharma, Inc. And Pfizer (PFE) Consumer Healthcare Enter Into Agreement To Commercialize 12-Hour Extended Release Dextromethorphan Cough Syrup Under The Robitussin Brand 6/29/2015 6:30:22 AM
Tris Pharma, Inc. Announces The FDA Acceptance Of NDA For Dyanavel XR 5/21/2015 6:26:28 AM